34108-14-0

Basic information

• Product Name: 4-benzylidene-2-(4-chlorophenyl)-1,3-oxazol-5(4H)-one
• CAS NO: 34108-14-0
• Molecular Formula: C₁₆H₁₀ClNO₂
• Molecular Weight: 283.7091
• Mol File: 34108-14-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 410.2°C at 760 mmHg
• Flash Point: 201.9°C
• Density: 1.27g/cm³
• Vapor Pressure: 6.15E-07mmHg at 25°C
• Refractive Index: 1.623
• CAS DataBase Reference: 4-benzylidene-2-(4-chlorophenyl)-1,3-oxazol-5(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-benzylidene-2-(4-chlorophenyl)-1,3-oxazol-5(4H)-one(34108-14-0)
• EPA Substance Registry System: 4-benzylidene-2-(4-chlorophenyl)-1,3-oxazol-5(4H)-one(34108-14-0)

Safety Data

• Hazardous Substances Data: 34108-14-0(Hazardous Substances Data)

Upstream product

• 13450-77-6 4-chlorohippuric acid 
• 100-52-7 benzaldehyde 
• 22887-53-2 2-(4-Chlorphenyl)-4,5-dihydro-1,3-oxazol-5-on 

Downstream Products

• 59490-25-4 α-(4-chloro-benzoylamino)-trans-cinnamic acid 
• 1323140-82-4 C₂₁H₂₀BrClN₂O₂ 
• 1323140-66-4 C₂₁H₂₀Cl₂N₂O₂ 

Relevant articles and documents

Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents

As a continuation of our previous work, a series of new phenyl acrylamide derivatives (4Aa-g, 4Ba-t, 5 and 6a-c) were designed and synthesized as non-nucleoside anti-HBV agents. Among them, compound 4Bs could potently inhibit HBV DNA replication in wild-type and lamivudine (3TC)/entecavir resistant HBV mutant strains with IC50 values of 0.19 and 0.18 μM, respectively. Notably, the selective index value of 4Bs was above 526, indicating the favorable safety profile. Interestingly, unlike nucleoside analogue 3TC, 4Bs could significantly inhibit 3.5 kb pgRNA expression. Molecular docking study revealed that 4Bs could fit well into the dimer-dimer interface of HBV core protein by hydrophobic, π–π and H-bond interactions. Considering the potent anti-HBV activity, low toxicity and diverse anti-HBV mechanism from that of nucleoside anti-HBV agent 3TC, compound 4Bs might be a promising lead to develop novel non-nucleoside anti-HBV therapeutic agents, and warranted further investigation.

Phenylpropenamide derivatives: Anti-hepatitis B virus activity of the Z isomer, SAR and the search for novel analogs

Phenylpropenamides have been reported to be a class of non-nucleoside inhibitors of the hepatitis B virus (HBV). This class of compounds was explored with the objective of developing potent anti-HBV agents, with a novel mechanism of action, that could be combined with nucleos(t)ide analogs currently used to treat HBV infection. To accomplish this objective a series of substituted arylpropenamide derivatives were prepared and the E and Z geometrical isomers were separated. The structural identity of each of the E and Z isomers was determined by single crystal X-ray crystallography. Contrary to previous reports, the activity of this class of molecules resides in the Z isomer. Further structure-activity relationship studies around the active Z isomer identified compounds that displayed potent antiviral activity against HBV with EC90 value of approximately 0.5 μM in vitro. Attempts to develop ring constrained analogs did not lead to active HBV inhibitors.

Synthesis of Some 2-Substituted 5-Oxo-4,5-dihydro-1,3-oxazoles and their Ring Cleavage Reactions with Aromatic Hydrocarbons

-